FDA Approves New Drug for Gout
The U.S. Food and Drug Administration (FDA) approved Krystexxa (pegloticase) Sept. 14 to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy.
Gout, which falls under ICD-9-CM diagnosis code 274.x, occurs due to an excess of the bodily waste uric acid, which is eventually deposited as needle-like crystals in the joints or in soft tissue. These crystals can cause intermittent swelling, redness, heat, pain, and stiffness in the joints. Gout is strongly associated with obesity, high blood pressure, high cholesterol, and diabetes, and occurs more often in men, in women after menopause, and in people with kidney disease.
“About 3 percent of the three million adults who suffer from gout are not helped by conventional therapy. This new drug offers an important new option for them,” said Badrul Chowdhury, M.D., director of the Division of Pulmonary, Allergy, and Rheumatology Products at the FDA’s Center for Drug Evaluation and Research.
For patients with gout, the conventional therapy is to receive drugs that lower the amount of uric acid in the blood. Krystexxa is an enzyme that lowers uric acid levels by metabolizing it into a harmless chemical that is excreted in the urine. The drug is administered to patients every two weeks as an intravenous infusion.
Since one out of every four patients in the clinical trials experienced a severe allergic reaction when receiving an infusion of Krystexxa, health care providers should dispense a corticosteroid and an antihistamine to their patients beforehand to minimize the risk of such a reaction. Other reactions during the clinical trials included gout flare, nausea, injection site bruising, irritation of the nasal passages, constipation, chest pain, and vomiting.
Physicians are also being warned to be cautious about administering Krystexxa to patients with congestive heart failure because the drug was not studied in this patient population.
Krystexxa is being approved with a Risk Evaluation and Mitigation Strategy that includes a medication guide for patients and materials for health care providers to communicate the risk of severe infusion and allergic reactions.
Krystexxa is manufactured by Savient Pharmaceuticals, Inc. of East Brunswick, N.J.
Source: FDA Press Release
Latest posts by admin aapc (see all)
- Message From Your Region 7 Representatives | October 2018 - October 24, 2018
- Message From Your Region 6 Representatives | October 2018 - October 24, 2018
- Message From Your Region 5 Representatives | October 2018 - October 24, 2018